ATE359076T1 - Mittel gegen juckreiz - Google Patents

Mittel gegen juckreiz

Info

Publication number
ATE359076T1
ATE359076T1 AT97912539T AT97912539T ATE359076T1 AT E359076 T1 ATE359076 T1 AT E359076T1 AT 97912539 T AT97912539 T AT 97912539T AT 97912539 T AT97912539 T AT 97912539T AT E359076 T1 ATE359076 T1 AT E359076T1
Authority
AT
Austria
Prior art keywords
remedies
itching
morphinian
antipruritic
opiate
Prior art date
Application number
AT97912539T
Other languages
English (en)
Inventor
Hiroshi Nagase
Jun Utsumi
Takashi Endoh
Toshiaki Tanaka
Junzo Kamei
Kuniaki Kawamura
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18041771&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE359076(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Toray Industries filed Critical Toray Industries
Application granted granted Critical
Publication of ATE359076T1 publication Critical patent/ATE359076T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Elimination Of Static Electricity (AREA)
  • Table Equipment (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Magnetic Record Carriers (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT97912539T 1996-11-25 1997-11-21 Mittel gegen juckreiz ATE359076T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP31347696 1996-11-25

Publications (1)

Publication Number Publication Date
ATE359076T1 true ATE359076T1 (de) 2007-05-15

Family

ID=18041771

Family Applications (3)

Application Number Title Priority Date Filing Date
AT03001739T ATE291429T1 (de) 1996-11-25 1997-11-21 Mittel gegen juckreiz
AT03001740T ATE263563T1 (de) 1996-11-25 1997-11-21 Mittel gegen juckreiz
AT97912539T ATE359076T1 (de) 1996-11-25 1997-11-21 Mittel gegen juckreiz

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT03001739T ATE291429T1 (de) 1996-11-25 1997-11-21 Mittel gegen juckreiz
AT03001740T ATE263563T1 (de) 1996-11-25 1997-11-21 Mittel gegen juckreiz

Country Status (15)

Country Link
US (2) US6174891B1 (de)
EP (5) EP0897726B1 (de)
KR (1) KR100557801B1 (de)
CN (3) CN1535687A (de)
AT (3) ATE291429T1 (de)
AU (1) AU738743B2 (de)
CA (1) CA2244256C (de)
DE (3) DE69728585T2 (de)
DK (1) DK0897726T3 (de)
ES (3) ES2215158T3 (de)
NO (1) NO316309B1 (de)
NZ (1) NZ331001A (de)
PT (1) PT897726E (de)
TW (1) TW542838B (de)
WO (1) WO1998023290A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763445A (en) 1996-03-08 1998-06-09 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
AU1290797A (en) * 1996-12-24 1998-07-17 George F. El Khoury Topical application of opioid drugs such as morphine for relief of itching and skin disease or irritation
JP2003526594A (ja) * 1997-07-14 2003-09-09 アドラー コーポレーション カッパ・アゴニスト抗掻痒薬学的製剤およびそれにより掻痒を治療する方法
JP3211027B2 (ja) * 1998-11-13 2001-09-25 丸石製薬株式会社 カプサイシン含有外用剤
WO2001014382A1 (en) * 1999-08-23 2001-03-01 Toray Industries, Inc. Analgesics containing as the active ingredient quaternary ammonium salt derivatives of morphinan
ES2308990T3 (es) 1999-08-24 2008-12-16 Toray Industries, Inc. Remedios para el dolor neuropatico y modelos animales de dolor neuropatico.
WO2001074819A1 (en) * 2000-04-03 2001-10-11 Toray Industries, Inc. Analgesics containing morphinan n-oxide derivatives as the active ingredient
JP2002249442A (ja) * 2001-02-21 2002-09-06 Fumakilla Ltd アレルギー減感作治療薬
JP4453254B2 (ja) * 2001-03-30 2010-04-21 東レ株式会社 レストレス・レッグズ症候群治療薬
US6617308B2 (en) 2001-04-30 2003-09-09 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1865 daltons
US7294688B2 (en) 2001-04-30 2007-11-13 Nanogen Inc. Biopolymer marker indicative of disease state having a molecular weight of 1348 daltons
JP4239592B2 (ja) * 2001-05-08 2009-03-18 東レ株式会社 敗血症治療剤
US6844438B2 (en) 2001-08-15 2005-01-18 Mclean Hospital Corporation N-substituted derivatives of morphinan and uses thereof
WO2003039561A1 (en) * 2001-11-02 2003-05-15 Elan Corporation, Plc Pharmaceutical composition
EP1496053B1 (de) 2002-03-29 2012-06-20 Santen Pharmaceutical Co., Ltd. Ein Kappa-opioid-Rezeptoragonist enthaltend ein 2-Phenylbenzothiazolinderivat
JP5189242B2 (ja) * 2002-09-23 2013-04-24 アルケルメス ファーマ アイルランド リミテッド 乱用抵抗性の医薬組成物
MXPA05003104A (es) * 2002-09-25 2005-05-27 Euro Celtique Sa Hidromorfonas n-sustituidas y uso de las mismas.
DE602005011113D1 (de) 2004-03-30 2009-01-02 Toray Industries Morphinanderivate als mittel gegen juckreiz
US7704522B2 (en) * 2004-09-08 2010-04-27 Clyde Morgan Topical medicament
US20060069086A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20060159748A1 (en) * 2004-12-23 2006-07-20 Rajesh Jain Oral immediate release formulation of a poorly water-soluble active substance
US7453122B2 (en) * 2005-02-08 2008-11-18 Taiwan Semiconductor Manufacturing Co., Ltd. SOI MOSFET device with reduced polysilicon loading on active area
CN101137658B (zh) * 2005-03-10 2011-06-08 东丽株式会社 用于与多发性硬化症伴随的搔痒的止痒剂
RU2397173C2 (ru) * 2005-04-06 2010-08-20 Торей Индастриз, Инк. Кристаллические производные морфинана и способ их получения
TW200806294A (en) * 2005-11-09 2008-02-01 Toray Industries Therapeutic or prophylactic agent for functional intestinal injury
CA2634055C (en) 2005-12-21 2011-07-05 Toray Industries, Inc. Antitussive agent
EP2099764B1 (de) * 2006-09-20 2011-07-27 Mallinckrodt Inc. Herstellung substituierter morphinan-6-one und salzen und zwischenprodukten davon
JP5875748B2 (ja) * 2007-03-06 2016-03-02 マリンクロッド エルエルシー 第４級ｎ−アルキルモルフィナンアルカロイド塩の調製のための方法
US9040726B2 (en) * 2007-03-06 2015-05-26 Mallinckrodt Llc Process for the preparation of quaternary N-alkyl morphinan alkaloid salts
MX2009011449A (es) 2007-04-24 2010-01-25 Toray Industries Agente terapeutico o profilactico para disquinesia.
CA2685131C (en) * 2007-04-26 2015-05-19 Toray Industries, Inc. Stable solid preparation containing 4,5-epoxymorphinan derivative
MX2009014181A (es) * 2007-06-22 2010-03-04 Toray Industries Remedio o preventivo para sindrome de disfuncion de integracion.
BRPI0817804A8 (pt) * 2007-10-05 2017-04-18 Toray Industries Agente terapêutico para melhorar as propriedades da pele compreendendo um derivado de morfinano ou qualquer um de seus sais de adição de ácido farmacologicamente permissíveis como um ingrediente ativo
WO2009138734A2 (en) * 2008-05-14 2009-11-19 Serentis Limited Use of opioid compounds in peripheral pain, wound healing and scar formation
EP2896614B1 (de) * 2008-05-27 2017-07-12 Mallinckrodt LLC Verfahren und Verbindungen zur Herstellung von Normorphinanen
WO2010028004A2 (en) 2008-09-03 2010-03-11 Mallinckrodt Inc. Substituted berbines and processes for their synthesis
CN102325777B (zh) * 2009-02-23 2015-08-12 马林克罗特公司 (+)-吗啡喃*n-氧化物及其制备方法
US8946419B2 (en) 2009-02-23 2015-02-03 Mallinckrodt Llc (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
JP5784507B2 (ja) * 2009-02-23 2015-09-24 マリンクロッド エルエルシー （＋）−モルフィナニウム第四級塩およびその生成方法
US8563724B2 (en) * 2009-02-23 2013-10-22 Mallinckrodt Llc (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
US8829020B2 (en) 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
PH12012501552A1 (en) 2010-01-29 2017-04-26 Toray Industries Therapeutic or prophylactic agent for biliary diseases
CN103327977B (zh) 2011-01-31 2016-05-04 东丽株式会社 恶液质的治疗或预防剂
KR20140063763A (ko) 2011-09-08 2014-05-27 말린크로트 엘엘씨 중간체를 단리하지 않는 알칼로이드의 제조 방법
JP6064252B2 (ja) * 2012-01-19 2017-01-25 三笠製薬株式会社 そう痒症改善経皮吸収貼付剤
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
JP2016506398A (ja) * 2012-12-14 2016-03-03 トレビ セラピューティクス インコーポレイテッド そう痒の処置法
WO2016052617A1 (ja) * 2014-09-30 2016-04-07 国立大学法人筑波大学 ナルフラフィン含有局所適用製剤
TW201707703A (zh) * 2015-06-04 2017-03-01 Tokai Capsule Co Ltd 軟膠囊劑
CN106866688B (zh) * 2015-12-10 2019-05-03 山东诚创医药技术开发有限公司 一种纳呋拉啡的精制方法
CA3017374A1 (en) * 2016-03-21 2017-09-28 Trevi Therapeutics, Inc. Treatment of uremic pruritus
WO2018103624A1 (zh) * 2016-12-06 2018-06-14 江苏恒瑞医药股份有限公司 一种κ阿片受体激动剂在制备治疗法尼醇X受体激动剂引起的瘙痒的药物中的用途
CA3091752A1 (en) 2018-03-08 2019-09-12 Victoria Link Ltd Treatment of demyelinating diseases
CN118512451A (zh) 2018-07-23 2024-08-20 特雷维治疗股份有限公司 慢性咳嗽、呼吸急促和呼吸困难的治疗
US20220226299A1 (en) * 2019-03-29 2022-07-21 Nippon Chemiphar Co., Ltd. Use of t-type calcium channel blocker for treating pruritus
IL294601A (en) 2020-01-10 2022-09-01 Trevi Therapeutics Inc Methods of administration of nalbuphine
KR20230031207A (ko) 2020-06-30 2023-03-07 도레이 카부시키가이샤 대사이상을 수반하는 질환 또는 증후군에 있어서의 근력 저하 증상의 개선제 또는 예방제
MX2023014819A (es) 2021-06-14 2024-03-21 Scorpion Therapeutics Inc Derivados de la urea que pueden ser utilizados para tratar el cancer.
WO2025095039A1 (ja) * 2023-10-31 2025-05-08 ティア・リサーチ・コンサルティング合同会社 皮膚疾患の医薬組成物、及び医薬品の新規用途探索方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU196376B (en) * 1985-05-23 1988-11-28 Sandoz Ag Process for preparing morphinane derivatives and pharmaceutical compositions containing such compounds
US5021413B1 (en) * 1988-08-24 1994-12-13 Sankyo Co Analgesic thiomorpholins, their preparation, and pharmaceutical compositions containing them
US5116842A (en) * 1989-05-18 1992-05-26 Glaxo Group Limited Chemical compounds
JP2525552B2 (ja) * 1992-01-23 1996-08-21 東レ株式会社 モルヒナン誘導体および医薬用途
JPH06122677A (ja) * 1992-08-28 1994-05-06 Sankyo Co Ltd 光学活性なカルボン酸アミド誘導体
CN1111900A (zh) * 1993-06-30 1995-11-15 东丽株式会社 止咳药
PL314036A1 (en) * 1993-10-20 1996-08-05 Boots Co Plc Pharmaceutical composition
IT1273751B (it) 1994-02-11 1997-07-10 Smithkline Beecham Farma Derivati azaciclici
JP2003526594A (ja) * 1997-07-14 2003-09-09 アドラー コーポレーション カッパ・アゴニスト抗掻痒薬学的製剤およびそれにより掻痒を治療する方法
US5760023A (en) 1997-07-14 1998-06-02 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith

Also Published As

Publication number Publication date
NO983431D0 (no) 1998-07-24
EP0897726A4 (de) 2003-05-28
TW542838B (en) 2003-07-21
DE69732868D1 (de) 2005-04-28
CN1535687A (zh) 2004-10-13
EP0897726B1 (de) 2007-04-11
US6174891B1 (en) 2001-01-16
EP1312361A1 (de) 2003-05-21
NO983431L (no) 1998-09-24
EP1310251A1 (de) 2003-05-14
DE69728585T2 (de) 2004-08-05
ES2215158T3 (es) 2004-10-01
NO316309B1 (no) 2004-01-12
US6316461B1 (en) 2001-11-13
EP1310255B1 (de) 2004-04-07
DE69737592D1 (de) 2007-05-24
CN1291717C (zh) 2006-12-27
ATE263563T1 (de) 2004-04-15
KR100557801B1 (ko) 2006-04-21
DE69732868T2 (de) 2006-04-13
CA2244256C (en) 2006-07-11
CN1180844C (zh) 2004-12-22
DK0897726T3 (da) 2007-08-13
PT897726E (pt) 2007-07-09
AU4968397A (en) 1998-06-22
EP1327444B1 (de) 2005-03-23
CN1214634A (zh) 1999-04-21
DE69737592T2 (de) 2008-01-03
CN1530111A (zh) 2004-09-22
ES2285733T3 (es) 2007-11-16
ES2236630T3 (es) 2005-07-16
EP1310255A1 (de) 2003-05-14
EP1327444A1 (de) 2003-07-16
CA2244256A1 (en) 1998-06-04
DE69728585D1 (de) 2004-05-13
ATE291429T1 (de) 2005-04-15
AU738743B2 (en) 2001-09-27
NZ331001A (en) 2000-05-26
KR19990081978A (ko) 1999-11-15
EP0897726A1 (de) 1999-02-24
JP3531170B2 (ja) 2004-05-24
WO1998023290A1 (en) 1998-06-04

Similar Documents

Publication Publication Date Title
ATE263563T1 (de) Mittel gegen juckreiz
DK0840732T3 (da) Substituerede benzolactamforbindelser som substans P-antagonister
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
PT800519E (pt) Compostos moduladores de receptores de esteroides e metodos
AU2002213336A1 (en) Substituted heterocyclic compounds for treating multidrug resistance
ID18883A (id) Pesaing 5-ht 1f
EA200300717A1 (ru) Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
ES2184127T3 (es) Derivados de sulfamato anticonvulsivos utiles para el tratamiento de la obesidad.
EA200300566A1 (ru) Применение cci-779 в качестве противоопухолевого средства
DE69928655D1 (de) Substituierte porphyrine
ES2190246T3 (es) Nuevos compuestos de tiazolopirimidina.
ES2192832T3 (es) Uso de compuestos macrolidos para tratar glaucoma.
PT1282418E (pt) Utilizacao de derivados pirazolo para o tratamento da infertilidade
PT977716E (pt) Utilizacao de alcoois como aditivos para rebocos e/ou argamassas
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
EA200300727A1 (ru) Производные 2h-1-бензопирана, способы их получения и их фармацевтические композиции
NO20002408D0 (no) 5-HT1F antagonister
BR0206917A (pt) Uso de antagonistas de mglur5 para o tratamento de condições prurìticas
NO20005548L (no) Mykobakterieinhibitorer
TR200100240T2 (tr) Anksiyete bozukluklarının tedavisi
BRPI0507987A (pt) métodos e compostos moduladores receptor de glicocorticóide
ATE267194T1 (de) Medikamente geeignet zur behandlung von proliferativen erkrankungen
MXPA05009428A (es) Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas.
ID27052A (id) Pengobatan arthritis dan keadaan-keadaan lain yang sekupa

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0897726

Country of ref document: EP